血友病治疗格局变化:对当前临床实验室凝血检测的影响
本综述探讨生物工程因子制品与非因子治疗时代血友病临床凝血检测面临的问题,包括传统凝血试验对新产品定量的局限、一步法凝血试验与显色底物试验用于临床决策和效价标签的长期争议,以及艾美赛珠单抗干扰所有基于aPTT的检测而使其结果不可靠。作者强调,临床医生必须了解本机构凝血检测方法及其潜在局限。
要点
- 艾美赛珠单抗干扰所有基于aPTT的检测,结果不可靠且可能误导不知情的医生。
- 新兴因子浓缩物加剧了对检测方法选择和可及性的担忧。
- 一步法凝血试验与显色底物试验用于临床决策和效价标签的争议已持续多年。
核心结论
- 在新生物工程因子制品和非因子治疗时代,传统凝血试验对部分新产品的定量出现问题。
- 临床医生了解本机构凝血检测方法及其潜在局限,对出血性疾病患者的管理至关重要。
研究设计与样本
- 综述,探讨临床环境下凝血检测的考虑因素,并强调了解本机构凝血检测及其潜在局限的重要性。
主要发现
- 艾美赛珠单抗干扰所有基于aPTT的检测,使其结果不可靠,并可能对不知情的医生产生虚假的安心感。
- 一步法凝血试验与显色底物试验用于临床决策和效价标签的讨论已持续多年。
- 新兴因子浓缩物加剧了对检测方法选择和可及性的担忧。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical coagulation assays are an integral part of diagnosing and managing patients with hemophilia; however, in this new era of bioengineered factor products and non-factor therapeutics, problems have arisen with use of traditional coagulation tests for the quantification of several of these new products. Discussion over the use of one-stage clotting assays versus chromogenic substrate assays for clinical decision making and potency labeling has been ongoing for many years. Emerging factor concentrates have heightened concern over assay selection and availability. Emicizumab interferes with all aPTT based assays, rendering them unreliable and potentially falsely reassuring to the unaware provider. This review explores considerations for coagulation assays in the clinical setting and highlights how awareness of institutional coagulation assays and potential limitations have never been more critical for providers caring for patients with bleeding disorders. This article is protected by copyright. All rights reserved.
引用
- Al-Samkari H, Croteau SE. Shifting Landscape of Hemophilia Therapy: Implications for Current Clinical Laboratory Coagulation Assays. Am J Hematol. 2018. PMID: 29884997. doi:10.1002/ajh.25153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。